Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD )
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Kaleb Tesfai und 29 weiteren Autor:innen. Beteiligte Einrichtung: MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Genetic Predisposition to Disease, Fatty Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Introduction
Previous studies have revealed conflicting results regarding liver fibrosis risk in lean metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to compare the risk of significant fibrosis in lean versus nonlean MASLD and identify fibrosis‐associated factors in lean MASLD.
Methods
The study was a cross‐sectional analysis of prospectively enrolled adults with MASLD. Individuals with lean MASLD were age‐ and sex‐matched with nonlean MASLD. Fibrosis assessment included vibration‐controlled transient elastography, magnetic resonance elastography and liver biopsy. A genetic risk score (GRS), summating the effect alleles of PNPLA3 and TM6SF2 minus the protective HSD17B13 genotype, was estimated to consider inherited genetic risk across BMI categories. Results were validated in an external Latin American cohort.
Results
The mean ( SD) age of 312 included participants with MASLD was 58.3 11.6 years and 69.2% were female. 44 (14.1%) individuals were lean, 90 (28.9%) were overweight, 90 (28.9%) had class I obesity and 88 (28.1%) had class II or greater obesity. The prevalence of significant fibrosis was 27.3% in lean and 31.1% in nonlean ( p = 0.653). Individuals with a high GRS had a higher prevalence of significant fibrosis compared to patients with low GRS (36.5% vs. 25.2%, p = 0.043) and the prevalence of significant fibrosis was similar in lean and nonlean patients with high GRS (31.3% vs. 37.1%, p = 0.645). The Latin American cohort exhibited similar results.
Conclusions
The prevalence of significant fibrosis and the effect of GRS were similar in lean and nonlean MASLD, highlighting that lean MASLD patients may have a comparable risk to overweight and obese MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
- Departamento De Gastroenterología, Escuela De Medicina, Pontificia Universidad Católica De Chile, Santiago, Chile.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
- Division of Gastroenterology and Hepatology, Western University & London Health Sciences Centre, London, Canada.
- Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Departamento De Gastroenterología, Hospital Escuela, Laboratorio De Biotecnología Molecular, Conicet, Universidad Nacional De Misiones, Posadas, Misiones, Argentina.
ORCID-Profile: Kaleb Tesfai, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese, Francisco Idalsoaga, Fernando Javier Barreyro, Adrian Gadano, Sebastián Marciano, Cristiane Villela-Nogueira, Claudia Alves Couto, Mísia Joyner de Sousa Dias Monteiro, Claudia P Oliveira, Mario G Pessoa, Mario Reis Alvares-da-Silva, Daniel Q Huang, Amit V Khera, Rohit Loomba, Veeral Ajmera
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- NIAAA NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
Zitieren
APA
Tesfai, K., Díaz, L. A., Arab, J. P., Arrese, M., Idalsoaga, F., Ayares, G., Agrawal, S., Barreyro, F. J., Gadano, A., Marciano, S., Morales, J. M., Villela-Nogueira, C., Leite, N., Salles, G., Cardoso, C. R., Couto, C. A., Theodoro, R., de Sousa Dias Monteiro, M. J., Oliveira, C. P., …, & Ajmera, V. (2026). Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ). Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70433
Vancouver
Tesfai K, Díaz LA, Arab JP, Arrese M, Idalsoaga F, Ayares G, et al. Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ). Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70433
BibTeX
@article{Tesfai2026,
author = {Tesfai, Kaleb and Díaz, Luis Antonio and Arab, Juan Pablo and Arrese, Marco and Idalsoaga, Francisco and Ayares, Gustavo and Agrawal, Saaket and Barreyro, Fernando Javier and Gadano, Adrian and Marciano, Sebastián and Morales, Jorge Martínez and Villela-Nogueira, Cristiane and Leite, Nathalie and Salles, Gil and Cardoso, Claudia Regina and Couto, Claudia Alves and Theodoro, Rafael and de Sousa Dias Monteiro, Mísia Joyner and Oliveira, Claudia P and Pessoa, Mario G and Alvares-da-Silva, Mario Reis and Huang, Daniel Q and Madamba, Egbert and Singh, Seema and Lokanadham, Snigdha and Bettencourt, Ricki and Richards, Lisa M and Khera, Amit V and Loomba, Rohit and Ajmera, Veeral},
title = {Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD )},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70433}
}
EUVIMED